Vijaya Diagnostic Centre Limited has informed the Exchange about Transcript
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vijaya Diagnostic reported a strong Q1 FY26 with consolidated revenue of Rs. 188 crores, up 20.4% year-on-year, driven by 17% volume growth and 14% patient footfall growth. EBITDA margin came in healthy at 39.1% with PAT margin at 20.4%, despite the launch of 5 new hubs and 1 spoke during the quarter. The company holds Rs. 270 crores in cash (Rs. 220 crores net of capital creditors). Five of the planned 10 hubs for FY26 are already operational, with 3 more to be commissioned in Q2 and 2 in H2. Full-year FY26 capex guidance is Rs. 150-155 crores for new centers, and EBITDA margin is guided at 38-38.5%, factoring in a 1-1.5% drag from new hubs. The management maintained its 15%+ revenue growth guidance backed by 13% volume growth, with wellness contribution at 14.2% and home collection at 3.2-3.3% of revenue.
Strong Q1 performance with revenue and margin beat reinforces the bull case; however, management's guidance of 38-38.5% full-year EBITDA (below Q1's 39.1%) signals some near-term margin pressure from new hub ramp-up. Stock may react positively to consistent execution, but the slightly softer margin guidance for the full year could temper expectations.